カプセル内視鏡市場：アクセサリー別、製品別、用途別、地域別、2026-2032年

カプセル内視鏡市場の評価、2026-2032年

クローン病や消化管出血のような疾患の症例の増加が、カプセル内視鏡の採用を推進しています。カプセルの設計とイメージング技術の革新は、診断精度と患者の経験を強化し、市場規模は2024年に2億9,230万米ドルを突破し、2032年までに約9億7,156万米ドルの評価に達することを推進しています。

これに加えて、消化管の健康と利用可能な診断オプションに関する意識の高まりが、カプセル内視鏡の採用に拍車をかけています。非侵襲的な診断方法への嗜好の高まりが、カプセル内視鏡の患者の受け入れと利用を促進し、2026年から2032年にかけて16.20%のCAGRで市場の成長を可能にしています。

カプセル内視鏡市場定義/概要

カプセル内視鏡検査は、胃腸（GI）管の走行画像を撮影する小型の錠剤サイズのカメラを飲み込む低侵襲診断手順です。通常、光源とカメラを備えたこの装置は、画像をワイヤレスで外部の記録装置に送信します。この技術により、小腸のような従来の内視鏡法では到達が困難な消化管の領域を詳細に可視化することができます。

カプセル内視鏡検査は主に、消化管出血、クローン病、小腸腫瘍などの診断に用いられます。原因不明の消化器症状を経験する患者にとって、多くの病態が気づかれない可能性のある小腸を包括的に見ることができるため、特に有益です。この検査は一般的に安全で非侵襲的であり、鎮静剤を必要としないため、多くの患者にとって魅力的な選択肢となっています。

胃腸疾患の有病率の増加はどのようにカプセル内視鏡の採用を増加させるか？

消化器疾患の有病率の上昇は、カプセル内視鏡市場の主要な促進要因です。国立糖尿病・消化器・腎臓病研究所によると、米国では約6,000万人から7,000万人が消化器疾患に罹患しています。このような患者数の増加により、低侵襲な診断ツールに対する需要が高まっています。カプセル内視鏡は、従来の内視鏡技術では検査が困難な小腸全体を、苦痛なく効率的に可視化する方法を提供します。2024年3月、メドトロニック社は、より強化された画像処理機能と改善されたバッテリー寿命を特徴とする新しいPillCam（TM）SB4システムの発売を発表しました。

カプセル内視鏡システムの技術的進歩が市場成長に拍車をかけています。より高解像度のカメラ、より長いバッテリー寿命、人工知能支援画像解析などの技術革新は、診断精度を向上させ、カプセル内視鏡の用途を拡大しています。これらの開発は、特に小腸腫瘍や不明瞭な消化管出血の検出に極めて重要です。世界保健機関（WHO）は、2020年には大腸がんが世界で3番目に多いがんとなり、193万人が新たに罹患すると報告しています。こうしたニーズの高まりを受けて、オリンパス株式会社は2024年2月、AIを活用した病変検出アルゴリズムを組み込んだ次世代カプセル内視鏡プラットフォームを発表しました。

価値観に基づくヘルスケアへのシフトと遠隔医療の導入拡大が、カプセル内視鏡市場を前進させています。カプセル内視鏡検査は、従来の内視鏡処置に代わる費用対効果の高い選択肢を提供し、入院や麻酔の必要性を低減します。メディケア&メディケイドサービスセンターは、遠隔医療訪問がCOVID-19パンデミックの間に、2019年の約84万件から2020年の5,270万件へと63倍に増加したと報告しました。この動向は持続しており、遠隔カプセル内視鏡処置の機会を生み出しています。

カプセル内視鏡検査に利用可能な償還オプションは限定的で、市場成長を抑制するか？

カプセル内視鏡市場は、この技術に関連する高コストのために大きな制限に直面しています。必要な画像処理ソフトや読影ソフトに加え、装置自体も高価な場合があります。この経済的負担は、特に医療予算が厳しい開発途上地域において、患者やヘルスケア施設にとってのアクセシビリティをしばしば制限します。高コストが医療提供者の間でこの技術の採用をためらわせ、市場全体の成長を制限することにもつながります。

もう1つの阻害要因は、カプセル内視鏡検査で利用できる償還オプションが比較的限られていることです。多くの保険業者は費用を完全にカバーしていないため、患者と医師の双方がこの診断ツールを選択する意欲を削ぐことになりかねないです。償還に関する標準化されたガイドラインがないことが状況をさらに複雑にしており、ヘルスケアプロバイダーが従来の方法と比較してカプセル内視鏡検査の費用を正当化することを困難にしています。

さらに、市場はデータ管理と分析に関する技術的課題によって阻害されています。カプセル内視鏡によって生成される膨大なデータには、処理と解釈のための高度なソフトウェアが必要です。しかし、画像解析と診断精度のための現在の機能は一貫していないことがあり、診断の見落としやフォローアップ処置の必要性についての懸念につながります。このような不確実性は、ヘルスケア専門家が主要な診断ツールとしてカプセル内視鏡に頼ることを躊躇させ、市場導入に影響を与える可能性があります。

目次

第1章 世界のカプセル内視鏡市場の導入

• 市場概要
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 世界のカプセル内視鏡市場展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 世界のカプセル内視鏡市場、アクセサリー別

• 概要
• ワイヤレスカプセル
• ワークステーションとレシーバー

第6章 世界のカプセル内視鏡市場：製品別

• 概要
• 小腸
• 食道
• 大腸

第7章 世界のカプセル内視鏡市場、用途別

• 概要
• クローン病
• OGIB（曖昧な消化管出血）
• 小腸腫瘍
• その他

第8章 世界のカプセル内視鏡市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他アジア太平洋地域
• 世界のその他の地域
  • ラテンアメリカ
  • 中東・アフリカ

第9章 世界のカプセル内視鏡市場の競合情勢

• 概要
• 各社の市場ランキング
• 主な発展戦略

第10章 企業プロファイル

• CapsoVision
• Given Imaging
• IntroMedic Co., Ltd.
• RF System lab
• Chongqing Jinshan Science & Technology（Group）Co., Ltd
• Olympus Corporation
• Fujifilm Holding Corporation

第11章 主な発展

• 製品上市／開発
• 合併と買収
• 事業拡大
• パートナーシップと提携

第12章 付録

• 関連調査

Capsule Endoscopy Market Valuation - 2026-2032

Rising cases of conditions like Crohn's disease and gastrointestinal bleeding is propelling the adoption of capsule endoscopy. Innovations in capsule design and imaging technology enhance diagnostic accuracy and patient experience is driving the market size surpass USD 292.3 Million valued in 2024 to reach a valuation of around USD 971.56 Million by 2032.

In addition to this, increased awareness about gastrointestinal health and available diagnostic options is spurring up the adoption of capsule endoscopy. The rising preference for non-invasive diagnostic methods drives patient acceptance and usage of capsule endoscopy is enabling the market grow at a CAGR of 16.20% from 2026 to 2032.

Capsule Endoscopy Market: Definition/ Overview

Capsule endoscopy is a minimally invasive diagnostic procedure that involves swallowing a small, pill-sized camera that captures images of the gastrointestinal (GI) tract as it travels through. The device, typically equipped with a light source and camera, transmits images wirelessly to an external recorder. This technique allows for detailed visualization of areas of the GI tract that are difficult to reach with traditional endoscopic methods, such as the small intestine.

Capsule endoscopy is primarily used for diagnosing conditions such as gastrointestinal bleeding, Crohn's disease, and small bowel tumors. It is particularly beneficial for patients who experience unexplained GI symptoms, as it provides a comprehensive view of the small intestine, where many pathologies may go unnoticed. The procedure is generally safe, non-invasive, and does not require sedation, making it an attractive option for many patients.

How will Rising Prevalence of Gastrointestinal Disorders Increase the Adoption of Capsule Endoscopy?

The rising prevalence of gastrointestinal disorders is a key driver of the capsule endoscopy market. According to the National Institute of Diabetes and Digestive and Kidney Diseases, approximately 60 to 70 million people in the United States are affected by digestive diseases. This increasing patient population has led to a growing demand for minimally invasive diagnostic tools. Capsule endoscopy offers a painless and efficient method for visualizing the entire small intestine, which is challenging to examine using traditional endoscopic techniques. In March 2024, Medtronic announced the launch of their new PillCam(TM) SB4 system, featuring enhanced imaging capabilities and improved battery life.

Technological advancements in capsule endoscopy systems are fueling market growth. Innovations such as higher resolution cameras, longer battery life, and artificial intelligence-assisted image analysis are improving diagnostic accuracy and expanding the applications of capsule endoscopy. These developments are particularly crucial for detecting small bowel tumors and obscure gastrointestinal bleeding. The World Health Organization reported that colorectal cancer was the third most common cancer worldwide in 2020, with 1.93 million new cases. In response to this growing need, Olympus Corporation unveiled its next-generation capsule endoscopy platform in February 2024, incorporating AI-powered lesion detection algorithms.

The shift towards value-based healthcare and the increasing adoption of telemedicine are driving the capsule endoscopy market forward. Capsule endoscopy offers a cost-effective alternative to traditional endoscopic procedures, reducing the need for hospital stays and anesthesia. The Centers for Medicare & Medicaid Services reported that telehealth visits increased by 63-fold during the COVID-19 pandemic, from approximately 840,000 in 2019 to 52.7 million in 2020. This trend has persisted, creating opportunities for remote capsule endoscopy procedures.

Will Limited Reimbursement Options Available for Capsule Endoscopy Restrain the Market Growth?

The capsule endoscopy market faces significant limitations due to the high costs associated with the technology. The devices themselves, along with the necessary imaging and interpretation software, can be expensive. This financial burden often restricts accessibility for patients and healthcare facilities, particularly in developing regions where healthcare budgets are tighter. The high cost can lead to hesitancy among providers to adopt the technology, limiting its overall market growth.

Another restraint is the relatively limited reimbursement options available for capsule endoscopy procedures. Many insurance providers do not fully cover the costs, which can discourage both patients and physicians from opting for this diagnostic tool. The lack of standardized guidelines for reimbursement further complicates the situation, making it challenging for healthcare providers to justify the expense of capsule endoscopy compared to traditional methods.

Additionally, the market is hindered by technological challenges related to data management and analysis. The vast amount of data generated by capsule endoscopes requires sophisticated software for processing and interpretation. However, the current capabilities for image analysis and diagnostic accuracy can be inconsistent, leading to concerns about missed diagnoses or the need for follow-up procedures. This uncertainty can deter healthcare professionals from relying on capsule endoscopy as a primary diagnostic tool, impacting market adoption.

Category-Wise Acumens

Will Rise in Adoption of Wireless Capsule Endoscopy Bolster Capsule Endoscopy Market Growth?

Wireless capsule endoscopy has emerged as the dominant technology in the capsule endoscopy market, revolutionizing gastrointestinal diagnostics. This non-invasive method allows for comprehensive visualization of the small intestine, which is challenging to examine using traditional endoscopic techniques. The U.S. Food and Drug Administration (FDA) reports that since the approval of the first wireless capsule endoscopy system in 2001, over 2 million procedures have been performed worldwide. The technology's ability to provide high-resolution images while minimizing patient discomfort has led to its widespread adoption.

The wireless capsule's dominance is further reinforced by its expanding applications beyond small bowel examination. Recent advancements have enabled its use in esophageal and colon screenings, broadening its clinical utility. According to the National Institute of Diabetes and Digestive and Kidney Diseases, colorectal cancer is the third most common cancer in both men and women in the United States, with an estimated 151,030 new cases in 2022. This prevalence underscores the importance of effective screening tools like wireless capsule endoscopy.

Which Factors Enhance the Use of Capsule Endoscopy to Diagnose Obscure Gastrointestinal Bleeding (OGIB)?

Obscure Gastrointestinal Bleeding (OGIB) has emerged as the dominant application in the capsule endoscopy market, driving significant growth and innovation. OGIB, defined as persistent or recurrent bleeding from the gastrointestinal tract with no identifiable source through conventional endoscopy, presents a unique diagnostic challenge that capsule endoscopy is uniquely positioned to address. According to the National Institute of Diabetes and Digestive and Kidney Diseases, OGIB accounts for approximately 5% of all gastrointestinal bleeding cases, with the small bowel being the most common source. Capsule endoscopy's ability to visualize the entire small intestine has made it an invaluable tool in diagnosing OGIB.

The prevalence of OGIB and its impact on patient quality of life have spurred technological advancements in capsule endoscopy systems. These improvements include higher resolution cameras, longer operating times, and artificial intelligence-assisted image analysis, all aimed at enhancing the detection of subtle bleeding sources. The American Journal of Gastroenterology reported that capsule endoscopy has a diagnostic yield of up to 67% in patients with OGIB, significantly higher than other diagnostic modalities. This high diagnostic yield has solidified capsule endoscopy's position as the gold standard for OGIB diagnosis.

Country/Region-wise Acumens

Will Presence Of Major Market Players in North America Fuel the Capsule Endoscopy Market Growth?

North America dominates the capsule endoscopy market, driven by a high prevalence of gastrointestinal disorders and advanced healthcare infrastructure. The region's leadership is underpinned by early adoption of innovative medical technologies and a robust reimbursement landscape. According to the Centers for Disease Control and Prevention (CDC), colorectal cancer is the third most common cancer in both men and women in the United States, with 151,030 new cases reported in 2022. This high incidence rate has fueled demand for advanced diagnostic tools like capsule endoscopy. In January 2024, Medtronic, a key player in the North American market, launched its next-generation PillCam(TM) SB4 system, featuring improved image resolution and a longer battery life, further solidifying the region's dominance in capsule endoscopy technology.

The presence of major market players and ongoing research and development activities contribute significantly to North America's leading position. The region boasts a high concentration of key manufacturers, fostering innovation and competitive pricing. The U.S. Food and Drug Administration (FDA) reported that since the first capsule endoscopy system approval in 2001, over 2 million procedures have been performed in the United States alone. This high adoption rate reflects the region's advanced healthcare system and willingness to embrace new technologies. In March 2024, Olympus Corporation announced the opening of a new research and development center in California, focusing on AI-powered image analysis for capsule endoscopy, highlighting the region's continued investment in advancing this technology.

Will Improving Access to Advanced Medical Technologies Enhance Adoption of Capsule Endoscopy in Asia Pacific?

The Asia Pacific region is experiencing rapid growth in the capsule endoscopy market, driven by increasing healthcare expenditure, rising awareness of gastrointestinal diseases, and improving access to advanced medical technologies. Countries like China, Japan, and India are at the forefront of this expansion, with their large populations and growing middle class contributing to increased demand for minimally invasive diagnostic tools. According to the World Health Organization, the incidence of colorectal cancer in Asia is expected to increase by 60% by 2030, reaching 1.5 million new cases annually. This alarming projection has spurred investment in early detection technologies.

Technological advancements and localization efforts by key market players are fueling the rapid growth of capsule endoscopy in Asia Pacific. The region's tech-savvy population and strong manufacturing capabilities have created a fertile ground for innovation in medical devices. The Indian Council of Medical Research reported that in 2023, there was a 15% increase in the adoption of capsule endoscopy procedures across major Indian hospitals compared to the previous year. This trend reflects the growing acceptance of the technology among healthcare providers and patients alike.

Competitive Landscape

The capsule endoscopy market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the capsule endoscopy market include:

• Given Imaging (Medtronic)
• Olympus Corporation
• Pentax Medical
• FujiFilm Corporation
• Siemens Healthineers
• Check-Cap Ltd.
• IntroMedic Co., Ltd.
• Capsovision, Inc.
• Medtronic
• BSC (Boston Scientific Corporation)
• Hoya Corporation
• Echosens
• Endocapsule (Olympus)
• Motus GI Holdings, Inc.
• STERIS plc
• C2N Diagnostics
• Medtronic (Acquisition of Given Imaging)
• VGI Health Technology
• Lumendi
• Kallistem

Latest Developments

• In September 2023, Medtronic announced the launch of its latest capsule endoscopy system, featuring advanced imaging technology that improves diagnostic accuracy for gastrointestinal disorders.
• In August 2023, a collaborative study published in the Journal of Gastroenterology highlighted the increasing efficacy of capsule endoscopy in detecting early-stage colorectal cancer, leading to growing demand in the market.

Capsule Endoscopy Market, By Category

• Accessories:
• Wireless Capsule
• Workstation and Receiver
• Product:
• Small Bowel
• Esophageal
• Colon
• Application:
• Crohn's Disease
• OGIB (Obscure Gastrointestinal Bleeding)
• Small Intestine Tumor
• Region:
• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL CAPSULE ENDOSCOPY MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL CAPSULE ENDOSCOPY MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL CAPSULE ENDOSCOPY MARKET, BY ACCESSORIES

• 5.1 Overview
• 5.2 Wireless Capsule
• 5.3 Workstation and Receiver

6 GLOBAL CAPSULE ENDOSCOPY MARKET, BY PRODUCT

• 6.1 Overview
• 6.2 Small Bowel
• 6.3 Esophageal
• 6.4 Colon

7 GLOBAL CAPSULE ENDOSCOPY MARKET, BY APPLICATION

• 7.1 Overview
• 7.2 Crohn's Disease
• 7.3 OGIB (Obscure Gastrointestinal Bleeding)
• 7.4 Small Intestine Tumor
• 7.5 Others

8 GLOBAL CAPSULE ENDOSCOPY MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East & Africa

9 GLOBAL CAPSULE ENDOSCOPY MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 CapsoVision
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Given Imaging
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 IntroMedic Co., Ltd.
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 RF System lab
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 Chongqing Jinshan Science & Technology (Group) Co., Ltd
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Olympus Corporation
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 Fujifilm Holding Corporation
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments

11 KEY DEVELOPMENTS

• 11.1 Product Launches/Developments
• 11.2 Mergers and Acquisitions
• 11.3 Business Expansions
• 11.4 Partnerships and Collaborations

12 Appendix

• 12.1 Related Research